Literature DB >> 25897080

Sequential Amyloid-β Degradation by the Matrix Metalloproteases MMP-2 and MMP-9.

Mar Hernandez-Guillamon1, Stephanie Mawhirt2, Steven Blais3, Joan Montaner4, Thomas A Neubert3, Agueda Rostagno2, Jorge Ghiso5.   

Abstract

Matrix metalloproteases (MMPs) MMP-2 and MMP-9 have been implicated in the physiological catabolism of Alzheimer's amyloid-β (Aβ). Conversely, their association with vascular amyloid deposits, blood-brain barrier disruption, and hemorrhagic transformations after ischemic stroke also highlights their involvement in pathological processes. To better understand this dichotomy, recombinant human (rh) MMP-2 and MMP-9 were incubated with Aβ40 and Aβ42, and the resulting proteolytic fragments were assessed via immunoprecipitation and quantitative mass spectrometry. Both MMPs generated Aβ fragments truncated only at the C terminus, ending at positions 34, 30, and 16. Using deuterated homologues as internal standards, we observed limited and relatively slow degradation of Aβ42 by rhMMP-2, although the enzyme cleaved >80% of Aβ40 during the 1st h of incubation. rhMMP-9 was significantly less effective, particularly in degrading Aβ(1-42), although the targeted peptide bonds were identical. Using Aβ(1-34) and Aβ(1-30), we demonstrated that these peptides are also substrates for both MMPs, cleaving Aβ(1-34) to produce Aβ(1-30) first and Aβ(1-16) subsequently. Consistent with the kinetics observed with full-length Aβ, rhMMP-9 degraded only a minute fraction of Aβ(1-34) and was even less effective in producing Aβ(1-16). Further degradation of Aβ(1-16) by either MMP-2 or MMP-9 was not observed even after prolonged incubation times. Notably, all MMP-generated C-terminally truncated Aβ fragments were highly soluble and did not exhibit fibrillogenic properties or induce cytotoxicity in human cerebral microvascular endothelial or neuronal cells supporting the notion that these truncated Aβ species are associated with clearance mechanisms rather than being key elements in the fibrillogenesis process.
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Alzheimer disease; amyloid-beta (Aβ); clearance/catabolism; mass spectrometry (MS); matrix metalloproteinase (MMP); peptides; proteolysis

Mesh:

Substances:

Year:  2015        PMID: 25897080      PMCID: PMC4463451          DOI: 10.1074/jbc.M114.610931

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  52 in total

1.  Beta-amyloid induces the production of active, matrix-degrading proteases in cultured rat astrocytes.

Authors:  Suman Deb; J Wenjun Zhang; Paul E Gottschall
Journal:  Brain Res       Date:  2003-04-25       Impact factor: 3.252

Review 2.  Aβ-degrading enzymes: potential for treatment of Alzheimer disease.

Authors:  James Scott Miners; Neil Barua; Patrick Gavin Kehoe; Steven Gill; Seth Love
Journal:  J Neuropathol Exp Neurol       Date:  2011-11       Impact factor: 3.685

3.  MMP-2/MMP-9 plasma level and brain expression in cerebral amyloid angiopathy-associated hemorrhagic stroke.

Authors:  Mar Hernandez-Guillamon; Elena Martinez-Saez; Pilar Delgado; Sophie Domingues-Montanari; Cristina Boada; Anna Penalba; Mercè Boada; Jorge Pagola; Olga Maisterra; David Rodriguez-Luna; Carlos A Molina; Alex Rovira; José Alvarez-Sabin; Arantxa Ortega-Aznar; Joan Montaner
Journal:  Brain Pathol       Date:  2011-09-15       Impact factor: 6.508

4.  Decreased clearance of CNS beta-amyloid in Alzheimer's disease.

Authors:  Kwasi G Mawuenyega; Wendy Sigurdson; Vitaliy Ovod; Ling Munsell; Tom Kasten; John C Morris; Kevin E Yarasheski; Randall J Bateman
Journal:  Science       Date:  2010-12-09       Impact factor: 47.728

5.  Collagenase-induced intracerebral hemorrhage in rats.

Authors:  G A Rosenberg; S Mun-Bryce; M Wesley; M Kornfeld
Journal:  Stroke       Date:  1990-05       Impact factor: 7.914

6.  Temporal profile of matrix metalloproteinases and their inhibitors after spontaneous intracerebral hemorrhage: relationship to clinical and radiological outcome.

Authors:  José Alvarez-Sabín; Pilar Delgado; Sònia Abilleira; Carlos A Molina; Juan Arenillas; Marc Ribó; Esteban Santamarina; Manolo Quintana; Jasone Monasterio; Joan Montaner
Journal:  Stroke       Date:  2004-04-15       Impact factor: 7.914

7.  TIMP-2 reduces proteolytic opening of blood-brain barrier by type IV collagenase.

Authors:  G A Rosenberg; M Kornfeld; E Estrada; R O Kelley; L A Liotta; W G Stetler-Stevenson
Journal:  Brain Res       Date:  1992-04-03       Impact factor: 3.252

8.  Matrix metalloproteinase-9 concentration after spontaneous intracerebral hemorrhage.

Authors:  Sònia Abilleira; Joan Montaner; Carlos A Molina; Jasone Monasterio; José Castillo; José Alvarez-Sabín
Journal:  J Neurosurg       Date:  2003-07       Impact factor: 5.115

9.  A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases.

Authors:  C G Knight; F Willenbrock; G Murphy
Journal:  FEBS Lett       Date:  1992-01-27       Impact factor: 4.124

Review 10.  The degradation of amyloid beta as a therapeutic strategy in Alzheimer's disease and cerebrovascular amyloidoses.

Authors:  Laura Morelli; Ramiro Llovera; Sandra Ibendahl; Eduardo M Castaño
Journal:  Neurochem Res       Date:  2002-11       Impact factor: 3.996

View more
  44 in total

1.  Aβ truncated species: Implications for brain clearance mechanisms and amyloid plaque deposition.

Authors:  Erwin Cabrera; Paul Mathews; Emiliya Mezhericher; Thomas G Beach; Jingjing Deng; Thomas A Neubert; Agueda Rostagno; Jorge Ghiso
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-07-13       Impact factor: 5.187

2.  Impaired Peripheral Lymphatic Function and Cerebrospinal Fluid Outflow in a Mouse Model of Alzheimer's Disease.

Authors:  Sunkuk Kwon; Ines Moreno-Gonzalez; Kathleen Taylor-Presse; George Edwards Iii; Nazaret Gamez; Olivia Calderon; Banghe Zhu; Fred Christian Velasquez; Claudio Soto; Eva M Sevick-Muraca
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

Review 3.  A Greek Tragedy: The Growing Complexity of Alzheimer Amyloid Precursor Protein Proteolysis.

Authors:  Robert J Andrew; Katherine A B Kellett; Gopal Thinakaran; Nigel M Hooper
Journal:  J Biol Chem       Date:  2016-07-29       Impact factor: 5.157

Review 4.  Metalloproteinases and their tissue inhibitors in Alzheimer's disease and other neurodegenerative disorders.

Authors:  Santiago Rivera; Laura García-González; Michel Khrestchatisky; Kévin Baranger
Journal:  Cell Mol Life Sci       Date:  2019-06-13       Impact factor: 9.261

Review 5.  Age-associated physiological and pathological changes at the blood-brain barrier: A review.

Authors:  Franciska Erdő; László Denes; Elizabeth de Lange
Journal:  J Cereb Blood Flow Metab       Date:  2016-11-11       Impact factor: 6.200

Review 6.  Are N- and C-terminally truncated Aβ species key pathological triggers in Alzheimer's disease?

Authors:  Julie Dunys; Audrey Valverde; Frédéric Checler
Journal:  J Biol Chem       Date:  2018-08-24       Impact factor: 5.157

Review 7.  Understanding the roles of mutations in the amyloid precursor protein in Alzheimer disease.

Authors:  S Hunter; C Brayne
Journal:  Mol Psychiatry       Date:  2017-11-07       Impact factor: 15.992

Review 8.  Vascular mTOR-dependent mechanisms linking the control of aging to Alzheimer's disease.

Authors:  Veronica Galvan; Matthew J Hart
Journal:  Biochim Biophys Acta       Date:  2015-11-27

9.  Meta-Analysis of Methamphetamine Modulation on Amyloid Precursor Protein through HMGB1 in Alzheimer's Disease.

Authors:  Sedra Alabed; Heping Zhou; Ilker K Sariyer; Sulie L Chang
Journal:  Int J Mol Sci       Date:  2021-04-30       Impact factor: 5.923

10.  Ion channel formation by N-terminally truncated Aβ (4-42): relevance for the pathogenesis of Alzheimer's disease.

Authors:  Abhijith G Karkisaval; Agueda Rostagno; Rustam Azimov; Deependra K Ban; Jorge Ghiso; Bruce L Kagan; Ratnesh Lal
Journal:  Nanomedicine       Date:  2020-06-10       Impact factor: 5.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.